Efficacy and Safety of an Orodispersible Vardenafil Formulation for the Treatment of Erectile Dysfunction in Elderly Men and Those with Underlying Conditions: An Integrated Analysis of Two Pivotal Trials

Journal of Sexual Medicine

Volumn 8, Issue 1, 2011, Pages 261-271

  Sperling, Herbert ^a   Gittelman, Marc ^b   Norenberg, Christiane ^c   Ulbrich, Ernst ^d   Ewald, Silke ^c  

^a KLINIKEN MARIA HILF GMBH   (Germany)

^b South Florida Medical Research   (United States)

^c BAYER PHARMA AG   (Germany)

^d BAYER AG   (Germany)

Author keywords

Diabetes mellitus; Dyslipidemia; Elderly; Erectile dysfunction; Hypertension; Orodispersible; Phosphodiesterase type 5 inhibitor; Vardenafil

Indexed keywords

VARDENAFIL;

AGED; ARTICLE; BACKACHE; DISEASE SEVERITY; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FORMULATION; DRUG SAFETY; DYSPEPSIA; ERECTILE DYSFUNCTION; FATIGUE; FLUSHING; HEADACHE; HUMAN; INTERNATIONAL INDEX OF ERECTILE FUNCTION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NOSE CONGESTION; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SUPRAVENTRICULAR PREMATURE BEAT; TREATMENT OUTCOME; XEROSTOMIA;

EID: 78650761617     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2010.02005.x     Document Type: Article

References (49)

1. NIH Consensus Conference. Impotence. NIH Consensus Development Panel on Impotence. JAMA 1993;270:83-90.
2. Laumann EO, Paik A, Rosen RC. Sexual dysfunction in the United States: Prevalence and predictors. JAMA 1999;281:537-44.
3. Rosen RC, Fisher WA, Eardley I, Niederberger C, Nadel A, Sand M. The multinational Men's Attitudes to Life Events and Sexuality (MALES) study: I. Prevalence of erectile dysfunction and related health concerns in the general population. Curr Med Res Opin 2004;20:607-17.
4. Corona G, Lee DM, Forti G, O'Connor DB, Maggi M, O'Neill TW, Pendleton N, Bartfai G, Boonen S, Casanueva FF, Finn JD, Giwercman A, Han TS, Huhtaniemi IT, Kula K, Lean ME, Punab M, Silman AJ, Vanderschueren D, Wu FC. Age-related changes in general and sexual health in middle-aged and older men: Results from the European Male Ageing Study (EMAS). J Sex Med 2010;7:1362-80.
5. Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay JB. Impotence and its medical and psychosocial correlates: Results of the Massachusetts Male Aging Study. J Urol 1994;151:54-61.
6. Martin-Morales A, Sanchez-Cruz JJ, Saenz de Tejada I, Rodriguez-Vela L, Jimenez-Cruz JF, Burgos-Rodriguez R. Prevalence and independent risk factors for erectile dysfunction in Spain: Results of the Epidemiologia de la Disfuncion Erectil Masculina Study. J Urol 2001;166:569-74 (discussion 574-575).
7. Rosen RC, Wing R, Schneider S, Gendrano N 3rd. Epidemiology of erectile dysfunction: The role of medical comorbidities and lifestyle factors. Urol Clin North Am 2005;32:403-17.
8. Teles AG, Carreira M, Alarcao V, Sociol D, Aragues JM, Lopes L, Mascarenhas M, Costa JG. Prevalence, severity, and risk factors for erectile dysfunction in a representative sample of 3, 548 Portuguese men aged 40 to 69 years attending primary healthcare centers: Results of the Portuguese erectile dysfunction study. J Sex Med 2008;5:1317-24.
9. Prins J, Blanker MH, Bohnen AM, Thomas S, Bosch JL. Prevalence of erectile dysfunction: A systematic review of population-based studies. Int J Impot Res 2002;14:422-32.
10. Inman BA, Sauver JL, Jacobson DJ, McGree ME, Nehra A, Lieber MM, Roger VL, Jacobsen SJ. A population-based, longitudinal study of erectile dysfunction and future coronary artery disease. Mayo Clin Proc 2009;84:108-13.
11. Kloner RA. Erectile dysfunction as a predictor of cardiovascular disease. Int J Impot Res 2008;20:460-5.
12. Montorsi P, Ravagnani PM, Galli S, Briganti A, Salonia A, Deho F, Schulman C, Montorsi F. Association between erectile dysfunction and coronary artery disease: A case report study. J Sex Med 2005;2:575-82.
13. Thompson IM, Tangen CM, Goodman PJ, Probstfield JL, Moinpour CM, Coltman CA. Erectile dysfunction and subsequent cardiovascular disease. JAMA 2005;294:2996-3002.
14. Corona G, Mannucci E, Forti G, Maggi M. Hypogonadism, ED, metabolic syndrome and obesity: A pathological link supporting cardiovascular diseases. Int J Androl 2009;32:587-98.
15. Feldman HA, Johannes CB, Derby CA, Kleinman KP, Mohr BA, Araujo AB, McKinlay JB. Erectile dysfunction and coronary risk factors: Prospective results from the Massachusetts Male Aging Study. Prev Med 2000;30:328-38.
16. Walczak MK, Lokhandwala N, Hodge MB, Guay AT. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med 2002;5:19-24.
17. Giuliano FA, Leriche A, Jaudinot EO, de Gendre AS. Prevalence of erectile dysfunction among 7, 689 patients with diabetes or hypertension, or both. Urology 2004;64:1196-201.
18. McCulloch DK, Campbell IW, Wu FC, Prescott RJ, Clarke BF. The prevalence of diabetic impotence. Diabetologia 1980;18:279-83.
19. Sasaki H, Yamasaki H, Ogawa K, Nanjo K, Kawamori R, Iwamoto Y, Katayama S, Shirai M. Prevalence and risk factors for erectile dysfunction in Japanese diabetics. Diabetes Res Clin Pract 2005;70:81-9.
20. Penson DF, Latini DM, Lubeck DP, Wallace KL, Henning JM, Lue TF. Do impotent men with diabetes have more severe erectile dysfunction and worse quality of life than the general population of impotent patients? Results from the Exploratory Comprehensive Evaluation of Erectile Dysfunction (ExCEED) database. Diabetes Care 2003;26:1093-9.
21. Roumeguere T, Wespes E, Carpentier Y, Hoffmann P, Schulman CC. Erectile dysfunction is associated with a high prevalence of hyperlipidemia and coronary heart disease risk. Eur Urol 2003;44:355-9.
22. Sun P, Swindle R. Are men with erectile dysfunction more likely to have hypertension than men without erectile dysfunction? A naturalistic national cohort study. J Urol 2005;174:244-8.
23. Montague DK, Jarow JP, Broderick GA, Dmochowski RR, Heaton JP, Lue TF, Milbank AJ, Nehra A, Sharlip ID. Chapter 1: The management of erectile dysfunction: An AUA update. J Urol 2005;174:230-9.
24. Wespes E, Amar E, Hatzichristou D, Hatzimouratidis K, Montorsi F, Pryor J, Vardi Y. EAU guidelines on erectile dysfunction: An update. Eur Urol 2006;49:806-15.
25. Cheng E. Real-life safety and efficacy of vardenafil in the treatment of erectile dysfunction-Results from 30, 010 U.S. patients. J Sex Med 2007;4:432-9.
26. Eardley I, Lee JC, Shabsigh R, Dean J, Maggi M, Neuser D, Norenberg C. Vardenafil improves erectile function in men with erectile dysfunction and associated underlying conditions, irrespective of the use of concomitant medications. J Sex Med 2010;7:244-55.
27. Edwards D, Hackett G, Collins O, Curram J. Vardenafil improves sexual function and treatment satisfaction in couples affected by erectile dysfunction (ED): A randomized, double-blind, placebo-controlled trial in PDE5 inhibitor-naive men with ED and their partners. J Sex Med 2006;3:1028-36.
28. Fisher WA, Rosen RC, Mollen M, Brock G, Karlin G, Pommerville P, Goldstein I, Bangerter K, Bandel TJ, Derogatis LR, Sand M. Improving the sexual quality of life of couples affected by erectile dysfunction: A double-blind, randomized, placebo-controlled trial of vardenafil. J Sex Med 2005;2:699-708.
29. Giuliano F, Rubio-Aurioles E, Kennelly M, Montorsi F, Kim ED, Finkbeiner AE, Pommerville PJ, Colopy MW, Wilkins HJ, Wachs BH. Efficacy and safety of vardenafil in men with erectile dysfunction caused by spinal cord injury. Neurology 2006;66:210-6.
30. ®) in a broad population of European men. Eur Urol 2004;45:634-41 (discussion 641).
31. Hellstrom WJ, Gittelman M, Karlin G, Segerson T, Thibonnier M, Taylor T, Padma-Nathan H. Vardenafil for treatment of men with erectile dysfunction: Efficacy and safety in a randomized, double-blind, placebo-controlled trial. J Androl 2002;23:763-71.
32. Ralph D, Eardley I, Kell P, Dean J, Hackett G, Collins O, Edwards D. Improvement in erectile function on vardenafil treatment correlates with treatment satisfaction in both patients and their partners. BJU Int 2007;100:130-6.
33. Stief C, Porst H, Saenz De Tejada I, Ulbrich E, Beneke M. Sustained efficacy and tolerability with vardenafil over 2 years of treatment in men with erectile dysfunction. Int J Clin Pract 2004;58:230-9.
34. Gittelman M, McMahon CG, Rodríguez-Rivera JA, Beneke M, Ulbrich E, Ewald S. The POTENT II randomised trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. Int J Clin Pract 2010;64:594-603.
35. Sperling H, Debruyne F, Boermans A, Beneke M, Ulbrich E, Ewald S. The POTENT I randomized trial: Efficacy and safety of an orodispersible vardenafil formulation for the treatment of erectile dysfunction. J Sex Med 2010;7:1497-507.
36. Goldstein I, Young JM, Fischer J, Bangerter K, Segerson T, Taylor T. Vardenafil, a new phosphodiesterase type 5 inhibitor, in the treatment of erectile dysfunction in men with diabetes: A multicenter double-blind placebo-controlled fixed-dose study. Diabetes Care 2003;26:777-83.
37. van Ahlen H, Wahle K, Kupper W, Yassin A, Reblin T, Neureither M. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives. J Sex Med 2005;2:856-64.
38. Carson CC, Rajfer J, Eardley I, Carrier S, Denne JS, Walker DJ, Shen W, Cordell WH. The efficacy and safety of tadalafil: An update. BJU Int 2004;93:1276-81.
39. Giuliano F, Jackson G, Montorsi F, Martin-Morales A, Raillard P. Safety of sildenafil citrate: Review of 67 double-blind placebo-controlled trials and the postmarketing safety database. Int J Clin Pract 2010;64:240-55.
40. Porst H, Young JM, Schmidt AC, Buvat J. Efficacy and tolerability of vardenafil for treatment of erectile dysfunction in patient subgroups. Urology 2003;62:519-23 (discussion 523-524).
41. Corona G, Razzoli E, Forti G, Maggi M. The use of phosphodiesterase 5 inhibitors with concomitant medications. J Endocrinol Invest 2008;31:799-808.
42. Miner M, Gilderman L, Bailen J, Cook D, Dawson K, Stanislaus M, Beresford E, Barnes A. Vardenafil in men with stable statin therapy and dyslipidemia. J Sex Med 2008;5:1455-67.
43. Valiquette L, Young JM, Moncada I, Porst H, Vezina JG, Stancil BN, Edmunds K, Montorsi F. Sustained efficacy and safety of vardenafil for treatment of erectile dysfunction: A randomized, double-blind, placebo-controlled study. Mayo Clin Proc 2005;80:1291-7.
44. Ziegler D, Merfort F, van Ahlen H, Yassin A, Reblin T, Neureither M. Efficacy and safety of flexible-dose vardenafil in men with type 1 diabetes and erectile dysfunction. J Sex Med 2006;3:883-91.
45. Dowson A, Bundy M, Salt R, Kilminster S. Patient preference for triptan formulations: A prospective study with zolmitriptan. Headache 2007;47:1144-51.
46. Dowson AJ, Almqvist P. Part III: The convenience of, and patient preference for, zolmitriptan orally disintegrating tablet. Curr Med Res Opin 2005;21(3 suppl):S13-7.
47. Hackett GI. Patient preferences in treatment of erectile dysfunction: The continuing importance of patient education. Clin Cornerstone 2005;7:57-65.
48. Jackson G, Giuliano F. Moderators' Introduction: Eur Heart J Suppl 2002;4(H suppl):H1-6.
49. Mirone V, Fusco F, Rossi A, Sicuteri R, Montorsi F. Tadalafil and vardenafil vs sildenafil: A review of patient-preference studies. BJU Int 2009;103:1212-7.